Fig. 4: Centrosome amplification is not associated with clinical features and disease outcome in HGSOC.
From: Molecular landscape and functional characterization of centrosome amplification in ovarian cancer
Comparison of CA scores across different (a) histotypes, (b) disease stages at diagnosis, (c) germline BRCA1/BRCA2 mutation status, and (d) surgery types during sample collection (IPS = immediate primary surgery; DPS = delayed primary surgery). e Comparison of CA tissue heterogeneity in IPS vs. DPS cases. f Comparison of mean centrosome size in IPS vs. DPS cases. Boxplots show 25th, 50th and 75th centiles; whiskers indicate 75th centile plus 1.5 × inter-quartile range and 25th centile less 1.5 × inter-quartile range. Notches on boxes extend 1.58 × inter-quartile range/sqrt(n) approximating to the 95% confidence interval for comparing medians. a,d–f show unpaired two-sided Wilcoxon tests. b–c Statistics shown is a Kruskal–Wallis one-way analysis of variance test. a–f depict 287 individual tumour samples (BriTROC, n = 194; OV04, n = 93). OV04 samples are shown in light blue, BriTROC samples are shown in dark blue. Note that for patients with multiple tissue samples, the median CA score across these tissues was used. Source data are provided as a Source Data file. g–h Forest plots of multivariable Cox proportional hazard modelling on overall survival for OV04 and BriTROC patients respectively with and without CA. Adjusted covariates included surgery type, stage and age. Squares display the hazard ratio (HR) and whiskers the 95% confidence intervals of the HR. p-values shown are derived from likelihood ratio tests.
